Skip To Main Content
Punnee Pitisuttithum on Muck Rack

Punnee Pitisuttithum

As seen in: Educational Studies, Environmental Communication, EClinicalMedicine, Pediatrics, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Punnee

Contact Punnee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines

|
By Punnee Pitisuttithum, Chukiat Sirivichayakul, Jittima Dhitavat, Arom Pitisuthitham
| EClinicalMedicine Verified
Abstract Background Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting antibody responses 2 and 3 years after booster vaccination with a new generation recombinant acellular pertussis vaccine.
Open in Who Shared Issue with article?

Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial

|
By Punnee Pitisuttithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Chiang Mai
| The Lancet Verified
Summary Background The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in preventing HIV acquisition. In this trial, we assessed the immunological effect of an additional vaccine boost to the RV144 regimen at varying intervals between the priming vaccine series and the boost. Methods RV306 is a double-blind, placebo-controlled, randomised clinical trial done at three clinical sites in Thailand.
Open in Who Shared Issue with article?

Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial

|
By Punnee Pitisuttithum, Kulkanya Chokephaibulkit, Chukiat Sirivichayakul, Sirintip Sricharoenchai
| The Lancet Verified
The immunogenicity of acellular pertussis vaccines and persistence of immunity after vaccination might be improved by using genetically inactivated pertussis toxin (PTgen) instead of chemically inactivated pertussis toxin (PTchem) because of the preservation of conformational epitopes. We assessed the safety and immunogenicity of two vaccines containing PTgen 1 year after vaccination.
Open in Who Shared Issue with article?
See all 9 articles